Risk of Abemaciclib-induced Liver Injury in Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer: A Retrospective Analysis

Acute-on-Chronic Liver Failure Incited by Cyclin-Dependent Kinase Inhibitor Therapy for Breast Cancer Effectively Treated With Liver Transplantation

“… 2 In fact, concomitant use of an aromatase inhibitor with abemaciclib has been identified as a significant risk factor of abemaciclib-induced liver injury. 3 The mechanism by which CDK4/6 inhibitors induce liver injury is not fully elucidated but may involve an idiosyncratic reaction from toxic or immunogenic intermediates or direct toxicity to hepatocytes by CDK inhibition. 1 Review of CDK4/6 inhibitor toxicity in a recent retrospective study suggests the possibility of safely rechallenging with an alternative CDK4/6 inhibitor, which may support the hypothesis that CDK4/6 inhibitors mediate idiosyncratic liver injuries.…”